阿维巴坦与克拉维酸对分枝杆菌β-内酰胺酶的抑制差异
本研究探讨缓慢生长与快速生长分枝杆菌的β-内酰胺酶(BlaC与Bla Mab)在Ambler第132位氨基酸差异对克拉维酸和阿维巴坦抑制特异性的影响。酶动力学及质谱分析显示,G132N与N132G替换对两种酶的抑制产生相反效应,导致对任一抑制剂获得耐药但非同时耐药。
要点
- BlaC的G132N替换使阿维巴坦抑制效力提高140倍,并因酰基酶水解废除克拉维酸抑制。
- Bla Mab的N132G替换使克拉维酸水解kcat降低5600倍,并使阿维巴坦氨甲酰化效力降低610倍。
- β-内酰胺酶催化特性改变导致对阿莫西林/克拉维酸与阿莫西林/阿维巴坦的敏感性发生相反转变。
核心结论
- G132N和N132G对BlaC与Bla Mab的抑制产生相反效应,提示这些替换可能导致对任一β-内酰胺酶抑制剂获得耐药,但不会同时对两者耐药。
研究设计与样本
- 通过酶动力学评估BlaC中G132N及Bla Mab中N132G替换对克拉维酸和阿维巴坦抑制的影响,用质谱评估酰基酶稳定性,并在大肠杆菌中表达β-内酰胺酶以测定药物组合的抗菌活性。
主要发现
- G132N替换使BlaC被阿维巴坦抑制的效力提高140倍,并因酰基酶水解而废除克拉维酸抑制。
- Bla Mab可高效水解克拉维酸,但N132G替换因稳定Bla Mab-克拉维酸共价加合物而使水解速率常数kcat降低5600倍。
- N132G替换还使Bla Mab被阿维巴坦氨甲酰化的效力降低610倍。
- β-内酰胺酶催化特性的改变导致对阿莫西林/克拉维酸和阿莫西林/阿维巴坦组合的敏感性发生从敏感到耐药及相反的转变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mycobacterium tuberculosis and Mycobacterium abscessus produce broad-spectrum class A β-lactamases, BlaC and Bla Mab , which are inhibited by clavulanate and avibactam, respectively. BlaC differs from Bla Mab at Ambler position 132 in the conserved motif SDN (SDG versus SDN, respectively). Here, we investigated whether this polymorphism could account for the inhibition specificity of β-lactamases from slowly and rapidly growing mycobacteria. METHODS: Enzyme kinetics were determined to assess the impact of the substitutions G 132 N in BlaC and N 132 G in Bla Mab on β-lactamase inhibition by clavulanate and avibactam. The stability of acylenzymes was evaluated by MS. The impact of the substitutions on the antibacterial activity of drug combinations was determined based on production of the β-lactamases in Escherichia coli . RESULTS: The substitution G 132 N increased 140-fold the efficacy of BlaC inhibition by avibactam and abolished clavulanate inhibition due to acylenzyme hydrolysis. Bla Mab efficiently hydrolysed clavulanate, but the substitution N 132 G led to a 5600-fold reduction in the hydrolysis rate constant k cat due to stabilization of Bla Mab -clavulanate covalent adducts. The N 132 G substitution also led to a 610-fold reduction in the efficacy of Bla Mab carbamylation by avibactam. Testing resistance to the amoxicillin/clavulanate and amoxicillin/avibactam combinations revealed that modifications in the catalytic properties of the β-lactamases resulted in opposite shifts from susceptibility to resistance and vice versa. CONCLUSIONS: G 132 N and N 132 G had opposite effects on the inhibition of BlaC and Bla Mab , indicating that these substitutions might lead to acquisition of resistance to either of the β-lactamase inhibitors, but not to both of them.
引用
- Soroka D, Ourghanlian C, Compain F, et al. Inhibition of β-lactamases of mycobacteria by avibactam and clavulanate. J Antimicrob Chemother. 2017. PMID: 28039278. doi:10.1093/jac/dkw546
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。